What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset posts 61–90

On post #73 — agreed on the reasoning, with one qualification.

Renal outcomes moved this compound out of the metabolic-only conversation. FLOW reported on kidney endpoints in people with type 2 diabetes and chronic kidney disease, which is a narrower population than the discussion here usually assumes.

I have written this out at length because the short version keeps being misread.

Since published dose-response for semaglutide keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

On published dose-response for semaglutide I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

Post #77 is right about the mechanism and I think understates the practical bit.

STEP 1 and STEP 4 are two different questions. The first asks what happens when treatment is added; the second asks what happens when it is withdrawn after a run-in. Quoting the first as evidence about maintenance is the commonest misreading of the programme.

Two people can read the same figure differently here and both be reasonable.

Post #77 put the caveat in the right place and I want to underline it.

On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.

Building on post #77 rather than restating it.

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.

I would treat that as a working assumption and revisit it.

Speaking only to published dose-response for semaglutide as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.

Published dose-response for semaglutide is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.

Post #82 is the version of this I will quote in future. One addition.

The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.

Where I part company with post #80, and it is a narrow parting.

For anyone finding this later: the short answer on published dose-response for semaglutide is that it depends on one thing, and the rest of the thread is people identifying which thing.

Adding a note of thanks rather than an opinion. I did not know most of that.

Post #84 describes the usual case. This is about the unusual one.

I keep a log for published dose-response for semaglutide specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.

Confirming post #86 from a second method, which matters more than confirming it from a second person.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

Worth saying I have only my own numbers here, and n is small.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

I keep a log of this specifically because memory is unreliable about it.

Post #86 answers the question as asked. The question underneath it is different.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

Before the thread moves on from published dose-response for semaglutide — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.